Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.39 Consensus Target Price from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $17.39.

Several brokerages recently issued reports on ROIV. Bank of America boosted their price target on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Piper Sandler boosted their price target on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Thursday, September 19th.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $11.37 on Wednesday. Roivant Sciences has a twelve month low of $8.24 and a twelve month high of $13.06. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. The stock has a market capitalization of $8.40 billion, a PE ratio of 2.25 and a beta of 1.25. The stock has a 50-day simple moving average of $11.51 and a 200 day simple moving average of $11.10.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The business had revenue of $55.10 million during the quarter, compared to analysts’ expectations of $30.72 million. During the same quarter in the previous year, the firm earned ($0.38) EPS. The firm’s revenue was up 155.1% compared to the same quarter last year. Research analysts anticipate that Roivant Sciences will post -1.14 EPS for the current year.

Insider Activity

In other news, CEO Matthew Gline sold 1,983,257 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the sale, the chief executive officer now directly owns 17,870,543 shares in the company, valued at approximately $210,693,701.97. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Rakhi Kumar sold 250,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total value of $2,972,500.00. Following the transaction, the chief accounting officer now directly owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew Gline sold 1,983,257 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the transaction, the chief executive officer now directly owns 17,870,543 shares in the company, valued at $210,693,701.97. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,477,309 shares of company stock worth $40,986,184. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ROIV. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Roivant Sciences by 26.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company’s stock worth $210,000 after acquiring an additional 3,955 shares in the last quarter. Norges Bank bought a new position in Roivant Sciences in the 4th quarter valued at $41,506,000. Dynamic Technology Lab Private Ltd boosted its position in Roivant Sciences by 35.1% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 17,155 shares of the company’s stock valued at $193,000 after buying an additional 4,458 shares during the last quarter. Decheng Capital LLC bought a new position in Roivant Sciences in the 4th quarter valued at $14,371,000. Finally, Treasurer of the State of North Carolina boosted its position in Roivant Sciences by 3.4% in the 4th quarter. Treasurer of the State of North Carolina now owns 157,830 shares of the company’s stock valued at $1,772,000 after buying an additional 5,190 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.